Test Price
2,800 AED✅ Home Collection Available
COL2A1 Gene Kniest Dysplasia Genetic Test in UAE | 2,800 AED | DNA Labs UAE
Executive Summary & Core Metrics
Clinical-Grade Accuracy & Premium UAE Service
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 accredited NGS workflow, validated by internal quality controls and external proficiency testing.
- Premium Logistics: Hospital-grade home collection by licensed phlebotomists using ISO-certified cold-chain transport. VIP mobile service available 8 AM–11 PM.
- Clinical Guidance: Complimentary post-test telephonic consultation with a clinical genetic specialist to interpret results and plan next steps.
- Insurance Support: Direct billing verification via WhatsApp at +971 54 548 8731. All major UAE insurers accepted.
Test Overview & Methodology
Comprehensive NGS of COL2A1 – Kniest Dysplasia & Type II Collagenopathies
This test utilises Next-Generation Sequencing to analyse the entire coding region of the COL2A1 gene, detecting single nucleotide variants, small insertions/deletions, and copy number changes linked to Kniest dysplasia and overlapping type II collagen disorders.
Clinical Intent: Confirmatory diagnosis in children and adults presenting with disproportionate short stature, midface hypoplasia, cleft palate, high myopia, retinal detachment, hearing loss, and characteristic skeletal dysplasia. Ordered primarily by Pediatricians, Neonatologists, and Medical Geneticists for precise molecular subtyping, family planning, and targeted surveillance.
| Feature | Our NGS Test (ISO 9001:2015) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Variant Coverage | Full gene ± flanking introns, CNV detection >2 exons | Targeted exons only; often misses deep intronic or large deletions |
| Turnaround Time | 3–4 weeks | 6–10 weeks (fragmented workflow) |
| Diagnostic Yield | Up to 98% for clinically typical Kniest dysplasia | ~85% in similar cohorts |
| Sample Flexibility | Whole Blood, Extracted DNA, Dried Blood Spot (FTA Card) | Usually requires high-quality extracted DNA |
| Price (AED) | 2,800 | 2,200 – 3,500 (variable) |
Physician Insight & Safety Protocols
“As a clinical geneticist managing skeletal dysplasia cases, I understand the complexity that a COL2A1 diagnosis brings to families. This NGS-based test provides definitive molecular evidence that directs orthopaedic surveillance, ophthalmology follow-up, and audiology monitoring. Results must always be integrated with the full clinical phenotype and family history for accurate counselling.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory – Medication & Test Preparation
⚠️ Important Pre-Test Guidance
Do not discontinue any prescribed medication or supplement without consulting your managing physician. Genetic test results inform long-term care but do not replace acute medical decisions. No fasting is required for this blood-based test.
Exclusion Criteria & Emergency Indicators
Do Not Proceed with Sample Collection If:
- Patient has received a whole blood transfusion within the last 14 days (may dilute germline DNA).
- Sample integrity is compromised (hemolysis, clotting, or insufficient volume).
- Inadequate clinical documentation or lack of consent from legal guardian (mandatory for minors per Federal Decree-Law No. 4 of 2016 on Medical Liability).
Seek Immediate Medical Attention If:
- Sudden severe joint pain or inability to bear weight.
- Acute respiratory distress or stridor.
- Acute vision loss, flashes, or sudden increase in floaters (retinal detachment).
- Signs of spinal cord compression (new onset leg weakness, incontinence).
Patient FAQ & Clinical Guidance
1. What is the clinical benefit of COL2A1 NGS testing for suspected Kniest dysplasia?
Direct answer: COL2A1 NGS confirms the molecular diagnosis of Kniest dysplasia and other type II collagenopathies with over 98% sensitivity, guiding targeted surveillance and familial risk assessment.
This test detects pathogenic variants across all 54 exons of the COL2A1 gene, including rare copy-number alterations that older methods miss. A positive result ends the diagnostic odyssey, enables precise genetic counselling for family planning, and triggers recommended screening for vision, hearing, and skeletal complications according to international guidelines.
2. What sample types are accepted and how does the home collection service work?
Direct answer: We accept whole blood, extracted DNA, or a single drop dried on an FTA card, with free home collection by DHA-licensed phlebotomists across all seven emirates.
Once you book via WhatsApp (+971 54 548 8731), a nurse arrives with a temperature-controlled kit. The sample is transported under ISO-certified cold chain to our Dubai laboratory. No fasting is required. For infants or anxious patients, a pediatric-friendly approach is used. Turnaround time is 3–4 weeks from receipt of a complete clinical form and signed consent.
3. Is genetic counselling included and what if my insurance denies the claim?
Direct answer: Pre- and post-genetic counselling sessions are included; if your insurer initially denies coverage, we provide a detailed medical necessity letter and direct billing appeal.
A certified genetic counsellor will draw a pedigree and explain the implications of a positive, negative, or variant of uncertain significance result. For self-pay patients, the 2,800 AED fee is fixed and fully transparent. We verify insurance eligibility before the blood draw via secure WhatsApp (+971 54 548 8731) to minimise out-of-pocket surprises.
UAE Regulatory & Data Privacy Adherence
Legal & Operational Compliance
All testing performed under DHA Facility License No. 1143. This service adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Laboratory accredited to ISO 9001:2015.
Clinical & Logistical Metadata
| Test Name | COL2A1 Gene Sequencing – Kniest Dysplasia & Type II Collagenopathies |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole Blood, Extracted DNA, Dried Blood Spot (FTA Card) |
| Methodology Used | Next-Generation Sequencing (NGS) – Full gene coding regions + flanking introns, CNV analysis |
| ICD-10-CM Code | Q77.7 |
| LOINC Code | 101356-6 |
| DHA Facility License & Laboratory Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians